
The effect of upfront intensive therapy on the prognosis of older patients with metastatic castration‐sensitive prostate cancer (mCSPC) remains unclear. Thus, the study assessed the impact of older age (≥75 years) on oncological outcomes in mCSPC patients with a high tumour burden. Patients aged ≥75 years who received upfront intensive therapy had significantly longer CRPC‐FS and OS compared with similar age patients treated with conventional therapy in real‐world practice. The oncological benefit may not diminish in this older population.
Like
Save
Share